Brief: Bioarctic Receives Royalty Of SEK 203.8 Mln For Q3 Sales Of Leqembi
28/10/2026 10:16
BRIEF-Bioarctic Receives Royalty Of SEK 203.8 Mln For Q3 Sales Of Leqembi Oct 28 (Reuters) - BioArctic AB (publ) BIOAb.ST:
SALES OF LEQEMBI® TOTALED 32.2 BILLION YEN IN THE THIRD QUARTER 2026
RECEIVES ROYALTY OF SEK 203.8 MILLION FOR Q3 2026, UP 74% FROM Q3 2025
ROYALTY TO BIOARCTIC AMOUNTING TO SEK 203.8 MILLION, WHICH IS AN INCREASE OF APPROXIMATELY 74 PERCENT
Source text: ID:nWkr5K2FGC
Further company coverage: [BIOAb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on BioArctic AB (publ)
See all newsBrief: Bioarctic Says Novartis Terminates Option, Collaboration And License Agreement With Bioarctic
Brief: Bioarctic Receives Royalty Of SEK 203.8 Mln For Q3 Sales Of Leqembi
Brief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi